News and Announcements
Proteomics International Laboratories Signs Largest Analytics Contract to Date & Becomes the World’s Most Accredited Protein Testing Lab
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Medical technology company Proteomics International Laboratories Ltd (ASX: PIQ) is pleased to provide the following update on its business activities for the three-month period to 30 June 2017.
KEY TAKEAWAYS:
- Validation study confirms PromarkerD can predict diabetic kidney disease better than any current measure.
- Results of the validation study were presented to world’s largest gathering of diabetes experts at the American Diabetes Association’s 77th Annual Scientific Sessions.
- New potential income stream through analytical services for clinical trials.
- Proteomics International became the world’s most accredited protein testing laboratory, and launched pharmacokinetic and companion diagnostic testing for clinical trials.
- Largest analytics contract to date (worth A$200,000) was signed, and year on year income growth is 28%. PIQ is aiming for its operations to be cashflow break even by the end of the 2017/18 financial year.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
